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By using a radioimmunoassay specific for cr-/V-acetyl /3-endorphin and its C-terminally shortened forms, we 
have established the presence of immunoreactive cc-N-acetyl endorphin (irNacEP) in extracts of five post- 
mortem human pituitary glands (2.27 + 0.64 ng/gland). This immunoreactivity has been further character- 
ized by subjecting these extracts to reverse-phase high-performance liquid chromatography (RP-HPLC). 
In all cases the major peaks of irNacEP co-migrated with synthetic human standard cr-N-acetyl a-endorphin 
(NacaEP), cr-N-acetyl y-endorphin (NacyEP) and NacbEP. These studies thus represent the initial demon- 
stration that a-A’-acetylation of /I-endorphin and its shorter molecular forms occurs in the human pituitary 
gland. 
Acetvlation 
1. INTRODUCTION 
,&Endorphin is a 31 amino acid opioid peptide 
b- Endorphin Human pituitary 
derived from the 31-kDa proopiomelanocortin 
(POMC) precursor. It was first isolated from the 
porcine pituitary gland [l], and subsequently 
shown to be further processed to C-terminally 
shortened forms @EPr -z,, PEP, - 16, PEPi _ r7 
(yEP) and PEPi - 16 (wEP) and/or -N-acetylated 
forms [2,3,4]. The pattern of post-translational 
processing to yield these various molecular forms 
differs between tissues and between species. For 
example, in the rat neuro-intermediate lobe (N-IL) 
the C-terminal derivatives of POMC are extensive- 
ly acetylated, with the predominant species being 
the longer (1-31, l-27 and l-26) a-N-acetylated 
forms of &endorphin; although the profile is 
qualitatively similar in the rat anterior pituitary 
(AP), the extent of acetylation is much less (< 5%) 
[51. 
In sheep N-IL, ,&-endorphin is predominantly 
processed to the shorter (NaccuEP, NacyEP and 
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Nac@EPr _ 27) forms. Though the sheep AP has a 
profile similar to the N-IL, the extent of acetyla- 
tion in sheep AP is much greater (25%) than in rat 
AP [5]. In bovine [6] and porcine [7] pituitaries cy- 
N-acetylation is essentially confined to the N-IL, 
with only minimal acetylation of PEP occurring in 
the AP. For the monkey, there are conflicting 
data. Weber et al. [6] reported low (5%) levels of 
acetylated forms in the AP by radioimmunoassay; 
other workers, using similarly N-acetyl-specific an- 
tiserum, have found much higher levels of ir- 
NacEP (25%) in monkey anterior pituitary [8]. 
In human AP, PEP was first characterized as 
PEP, -3, with a small amount of PEP1 _17 [9]. 
More recently, however, the C-terminally short- 
ened forms (a- and y-endorphin) have also been 
demonstrated [lo]. In neither of these studies, 
however, was it possible to show the presence of 
any a-N-acetylated species. Here we have used 
specific cu-N-acetyl endorphin radioimmunoassay 
and RP-HPLC, and by these means have estab- 
lished the presence of cu-N-acetyl a-endorphin, LY- 
N-acetyl y-endorphin and a-N-acetyl ,&-endorphin 
in the human pituitary for the first time. 
Published by Elsevier Science Publishers 6. V. (Biomedical Divwon) 
00145793/85/$3.30 @I 1985 Federation of European Biochemical Societies 109 
Volume 185, number 1 FEBS LETTERS June 1985 
2. MATERIALS AND METHODS 
2. I . Extraction 
Five human pituitaries were obtained at autopsy 
(lo-48 h post-mortem) and extracted at 4°C in 2 
ml of 0.1 M HCl by homogenizing with a Polytron 
(Brinkman Instruments, Westbury, NY; speed set- 
ting 2.5, 1 x 5 s burst). Homogenates were centri- 
fuged (15 000 x g, 30 min at 4’C); supernatants 
were either diluted for radioimmunoassay (RIA) or 
100~1 aliquots subjected to RP-HPLC. 
2.2. HPLC 
Extracts were chromatographed on a Nova Pak 
C-18 radial compression column (Waters Assoc.) 
as described [ll]. The column was eluted with a 
linear gradient of 30-80% B for 30 min at 1 
ml/min, where A is 11 mM trifluoroacetic acid 
(TFA), 3.6 mM acetic acid and B is 11 mM TFA 
containing 70% acetonitrile, The eluant was 
monitored at 214 nm. Fractions (0.5 ml) were 
evaporated and redissolved in the appropriate buf- 
fer prior to RIA. 
2.3. Radioimmunoassay 
The antiserum (R92) used for the radioim- 
munoassay has been described in [ 121. It was raised 
against synthetic bovine cu-hi-acetyl PEPi - 27, and 
does not recognize cuMSH, N-acetylated growth 
hormone fragments (provided by Professor J. 
Bornstein, Monash University), any of the en- 
kephalins or any non-acetylated POMC-derived 
peptides; specifically, no displacement of tracer is 
seen with 1 pg of,&EPi _ 31, (rEP or yEP. The an- 
tibody, however, cross-reacts 100% on a molar 
basis with cr-ll’-acetyl cvEP and longer acetylated 
forms. 
3. RESULTS 
Table 1 shows the levels of NacEP in extracts of 
5 pituitaries. There appears to be no significant 
correlation with age or time after death. Fig.1 
shows a typical profile of irNacEP in a human 
pituitary extract. The major peak of immunoreac- 
tivity elutes in the position of hNac@EP, with two 
smaller peaks eluting with hNamEP and hNacyEP. 
Three smaller peaks (l-3), although not formahy 
characterized, elute in the positions of the methio- 
nine sulphoxide forms of human NaccuEP, 
110 
Table 1 
Levels of immunoreactive NacEP in extracts of 5 
pituitaries 
Age Sex PM delay irNacEP 
(h) (ng/gland) 
1 82 M 24 2.29 
2 66 M 13 1.92 
3 83 M 48 1.44 
4 59 M 14 3.15 
S 82 M IO 2.57 
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Fig.]. Profile of IV-acetyl endorphin immunoreactivity 
after RP-HPLC of acid extracts of human pituitary 
tissue. Fractions were collected at 0.5 min intervals; the 
elution time of synthetic (h) standards were determined 
by UV absorbance (214 nm) in separate runs. 
NacrEP and Nac@EP. This oxidation is possibly 
an artifact of the extraction procedure. 
4. DISCUSSION 
The human pituitary gland is unique in that it 
lacks a discrete pars intermedia, the classical site of 
a-&‘-acetylation of ,&-endorphin in lower mammals. 
Here we have demonstrated the presence of 
irNacEP in the human pituitary gland, though rhe 
levels represent Q 1% of the total pituitary ir-endor- 
phin. The RP-HPLC profile of irNacEP appears to 
mirror that of non-acetylated PEP already charac- 
terised in the anterior pituitary [9,10], with NacPEP 
being the major species and two slightly lesser peaks 
of NawEP and NacyEP. Unlike other species 
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studied, there is Iittle~EP~ - 27 or Nac@EPt - 27, and 
no PEP, _ 26 or Nac@EPr _ 26. This is presumably 
due to substitution of the histidyl residue at posi- 
tion 27 in other species by tyrosine, which is less 
susceptible to general endopeptidase activity and 
removal by exopeptidases. 
In no species have physiological roles for pitui- 
tary PEP or its shorter/acetylated forms been 
established. It has been shown that a-N-acetylation 
of PEP and its C-terminally shortened fragments 
renders them opiate-receptor inactive [4]. However, 
there have been reported specific receptors recog- 
nising the C-terminus of @P, its N-terminally 
shortened forms, and (by extrapolation) its (Y-N- 
acetylated forms [ 131. Since the acetylation of the 
N-terminal tyrosyl residue protects the peptide 
against aminopeptidase degradation, N-acetylated 
/3EPr - 31 may thus represent a relatively stable 
ligand for such C-terminus specific receptors. An 
alternative role of N-acetylation, particularly for 
the shorter fragments (u- and y-EP) may also be in 
preventing the formation of des-tyr forms, which 
have been shown, for example, to have specific 
pharmacological effects [ 14,15]. 
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